PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
ASX:PYC
Price:
0.105 AUD
5%
Market Closed
Updated:
Jun 1, 2024
PYC Therapeutics Ltd
Cash Equivalents
|
PYC Therapeutics Ltd
Cash Equivalents Peer Comparison
Comparables:
IMM
MSB
CSL
CUV
TLX
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash Equivalents
AU$25.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
19%
|
|
|
Immutep Ltd
ASX:IMM
|
Cash Equivalents
AU$9.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-6%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash Equivalents
AU$38.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is PYC Therapeutics Ltd's Cash Equivalents?
Cash Equivalents
25.4m
AUD
25.4m
AUD
Based on the financial report for Dec 31, 2023, PYC Therapeutics Ltd's Cash Equivalents amounts to 25.4m AUD.
What is PYC Therapeutics Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
19%
19%
Over the last year, the Cash Equivalents growth was 49%. The average annual Cash Equivalents growth rates for PYC Therapeutics Ltd have been 2% over the past three years , 19% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
